Human CD19-CD22 Targeted T Cells Injection

DRUG2 trials

Sponsors

Hrain Biotechnology Co., Ltd.

Conditions

Acute Lymphoblastic LeukemiaCentral Nervous System Lymphoma

Early Phase 1

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Active, not recruitingNCT05651178

Hrain Biotechnology Co., Ltd.Central Nervous System Lymphoma

Start: 2022-08-12End: 2027-05-31Target: 10Updated: 2026-06-04

Phase 1

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Hrain Biotechnology Co., Ltd.Acute Lymphoblastic Leukemia

Start: 2022-02-10End: 2025-03-10Target: 18Updated: 2022-02-04